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Kinetics of '251-j32-microglobulin turnover in dialyzed patients. The
kinetics of /32.microglobulin (thm) were studied in 17 anephric or
functionally anephric hemodialyzed patients and five healthy subjects
as controls. Highly purified 132m was radiolabeled with 1251 and infused
into patients. The radioactivity in plasma and dialysis fluids was
measured during a week including two or three dialysis sessions.
Patients were classified in four groups according to treatment: hemodi-
alysis on Cuprophan (N = 5) or on AN69 membranes (N = 5),
hemofiltration (N = 4) and CAPD (N = 3). Plasma activity was fitted to
a three compartment model. In controls almost 100% of the radioactiv-
ity was recovered in urine within 96 hours and there was no extrarenal
catabolism. In patients the fractional catabolic rate ranged from 0.0008
to 0.0022 min' versus 0.026 to 0.047 min in controls. The synthetic
rate was within the range of values from controls in 10 patients but
higher in the seven others. It was correlated with plasma /32m concen-
tration. Kinetic data indicate a retention of intact /32m. The original
model was therefore modified with an additional compartment repre-
senting /32m captation. The amount of capted /32m was more elevated in
hemodialyzed patients than in patients treated by hemofiltration or
CAPD, in whom it could reach 5 mg/kg/day. Hemofiltration or CAPD
may eliminate about 30 to 100% of 132m produced and therefore
contribute to the low captation amount of these patients, as compared
with that of patients treated by hemodialysis.
Beta-2-microglobulin (/32m) was first characterized in the
urine of patients with Wilson's disease and in workers with
chronic cadmium poisoning [1]. The protein is found in a variety
of biological fluids and at the surface of nearly all cells associ-
ated with the heavy chain of class I antigen [21, or with
structurally related molecules as CD1 [3].
Serum /32m levels are increased in renal insufficiency [4] and
in a various malignancies, viral diseases and auto-immune
disorders. Patients on long-term hemodialysis have a high
prevalence of the carpal tunel syndrome, bone cysts and
pathologic fractures due to or associated with the deposition of
amyloid deposits, of which 32m is a major component [5—7].
The discovery of this new form of amyloidosis initiated
numerous investigations to document the cellular origin of p2m
and to measure its turnover in hemodialyzed patients [8, 91.
Cellulosic membranes, which are frequently used in hemodial-
ysis, stimulate /32m shedding from circulating cells through
complement and noncomplement mediated activation [10—121.
In vivo, the magnitude of this phenomenon is difficult to
ascertain since postdialysis serum /32m levels are increased by
extracellular fluid volume contraction and intracellular water
shift [13]. In contrast with cellulosic membranes, hemodialysis
with synthetic high permeable membranes induces a transient
decrease of /32m levels. Since these membranes are permeable
to and bind f32m, their use has been recommended to postpone
amyloidosis [14—17], but their possible advantage in this respect
has not been demonstrated by prospective clinical trials.
Metabolic studies in humans [18, 19] and in animals [20—22]
have clearly demonstrated that the kidney is the main site of
/32m catabolism. In the absence of kidney, /32m degradation is
delayed, and little is known on the proteolytic processes which
could operate outside the proximal tubules. The aim of this
study was to measure j32m kinetics of radioiodinated human
f32m in patients with end-stage renal failure, to evaluate the
possible role of dialysis strategy in modulating the turnover of
the molecule.
Methods
Patients
Seventeen patients with chronic renal failure and five healthy
subjects were included in the study. They gave informed
consent and the study was approved by the Ethical Committee
of the Medical School. All the patients were in steady condi-
tions and treated with either chronic hemodialysis or continu-
ous ambulatory peritoneal dialysis (CAPD). Dialysis had been
performed with the same artificial membrane since the begin-
fling of therapy: five patients were dialyzed with Cuprophan
membrane (HD Cup), and five with the highly permeable
polyacrilonitnie membrane AN69 (HD AN69). Four patients
were treated with post-dilution hemofiltration (HF) using
polysulfone membranes, and three were on CAPD (Table 1).
Dialysis sessions lasted for an average of four hours and 25
liters of fluid were exchanged by hemofiltration. To prevent
thyroidal uptake of 125J all subjects received 40 mg of potas-
sium iodide per day during the study, starting three days before
the administration of 1251 p2m.
Isolation and labeling of 2m
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/32m was isolated from the urine of hemodialysis patients
having residual diuresis. Briefly, urine was passed through a
column of immunopurified sheep anti-human f32m antibodies
immobilized on silica beads. The material eluted by pH shift
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Table 1. Basic parameters from studied subjects
Name
Dialysis
treatment Sex
Weight
kg Age
Diuresis
liter/day
/32m
mg/liter
Vp
liter
Sp
mg
JPR Control M 64 45 1.90 1.70 3.590 6.10
CLV Control M 56 37 1.48 1.50 3.142 4.71
JMH Control M 67.5 32 0.80 1.10 3.350 3.69
SRI Control M 68 32 1.33 1.02 3.800 3.88
JBR Control M 72 45 1.55 1.90 4.008 7.61
POQ HD cup M 41 65 0.3 57.0 2.054 117
SAB HD cup F 60.5 60 0 69.0 3.394 234
HOU HD cup M 66.5 68 0 45.0 3.731 168
CAR HD cup M 56.5 76 0.8 20.5 3.655 74.9
DEL HD cup M 51.5 73 0.2 29.9 3.158 94.4
PIQ HD AN69 M 68 58 0 28.0 3.830 107
HEL HD AN69 M 63.5 58 0 42.0 3.548 149
CIV HD AN69 M 58.5 78 0 61.0 3.274 200
TAD HD AN69 F 75 60 0 42.0 4.224 177
LAM HD AN69 F 74.3 57 0 17.0 4.136 70.3
MAZ HF M 59 54 0 22.0 2.501 55.0
JAC HF F 51 83 0 35.0 2.884 101
JAO HF F 53 78 0 30.7 2.997 92.0
OLI HF F 43.5 52 anephric 37.8 2.496 94.3
SAL CAPD F 60.5 61 0 19.7 3.407 67.1
DUF CAPD F 46 54 0 65.8 2.247 148
HAU CAPD H 44.5 47 0 43.5 2.611 114
was the plasmatic volume calculated by isotopic dilution and S, the amount of f32m in the plasmatic volume.
was fractionated by preparative isoelectrofocusing on granu-
lated gel in the presence of Ampholytes (pH 4 to 6). The
material recovered in the pH 5.7 zone was chromatographed on
AcA 54 gel. The purity of f32m was checked by two-dimensional
electrophoresis followed by silver staining, and the integrity of
the molecule by immunoblotting with radiolabeled anti-2m
antibodies.
Three mg samples of /32m were labeled with iodine 125 by the
iodine monochloride method of McFarlane [231 and diluted with
the same amount of cold /32m. Unbound radioactivity was
removed by centrifugation on AcA 202 gel. Labeled /32m was
treated with Detoxigel (Pierce, Rockford, Illinois, USA) to
eliminate pyrogens, then sterilized by filtration on Millipore
0.22 and distributed into four vials. Each vial contained a test
dose of 1 to 1.2 mg of protein labeled with 8.1 to 11.1 MBq of
1251 according to the yield of the labeling. After injection,
'251-J32m remaining in the vial was stored at 4°C. After the
completion of the study, analysis of the molecule by either
chromatography on Superose 12 gel (Pharmacia) or SDS-PAGE
electrophoresis indicated the absence of degradation or aggre-
gation.
Protocol and analytical methods
Labeled f32m was diluted with 5 ml of saline and administered
intravenously. The exact amount of injected 32m was calcu-
lated by double determination of the weight of the syringes
before and after injection. One to 2 ml heparinized blood
samples were collected from an intravenous indwelling catheter
placed in the controlateral forearm 1, 3, 5, 10, 30 minutes, 1, 2,
4, 6, 12 and 24 hours after injection, then every 24 hours during
four to seven days. On the day of hemodialysis a sample was
taken immediately before the beginning of the session, then
every 20 minutes and 1, 2 and 4 hours after the end of the
session.
The following procedure was applied to each blood sample
just after collection: centrifugation for 10 minutes at 400 g at
4°C; isolation of plasma; determination of protein bound radio-
activity and of "free radioactivity" contained in the superna-
tant obtained after trichloracetic acid precipitation (10% volt
vol); and measurement of f32m concentration by ELISA [241.
The samples were stored at —20°C. Later they were analyzed
by SDS-PAGE chromatography followed by autoradiography
or chromatographed on Superose 12 gels by FPLC (Pharmacia).
Urine samples, ii any, were collected daily, and dialysate
fluids were collected immediately. Free and bound radioactivity
as determined by TCA precipitation and samples were frozen
for further f32m determination by ELISA.
Modeling
For calculations, the data which comprise the period between
the injection time and the first dialysis session were used. The
plasma disappearance curves of TCA-precipitable radioactivity
in healthy controls could be described by a two compartment
model by standard methods of graphical analysis. However, in
uremic patients a three compartment model was best fitted as
assessed by analysis of variance. The general equation describ-
ing the decay of the tracer in the plasma was:
x1(t) = X11e" + Xi2e_2t + X —a3t (Eq. 1)
where x1 is expressed in relative specific activity, X is the
coefficient of the ith exponential term given by the ordinate
intercept of the exponential term and a, the exponential con-
stant in the exponential term (fraction per hr). The need of
three exponential components to describe the plasma curve
indicates that the system should correspond to at least three
compartments. The distribution volume is the sum of the
compartment volumes which includes plasma volume (compart-
ment 1) in which the tracer is administered and extravascular
compartments (2 plus 3). The fraction of injected dose in
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Fig. 1. Chromatographic analysis by FPLC
of a serum sample taken 720 minutes after
tracer injection in patient CAR. Fifty
microliter samples of serum were injected on
a Superose 12 column (HR 30/10) and
followed for absorbance ( ) and
radioactivity ( ). The column was
calibrated with IgG, human serum albumin
and Bl2 vitamin (1.35 kDa). The profile of
radioactivity of freshly labeled f32m was
superimposed as reference (— — —).
q1(t) = A,ie_t + A12e_a2t + A13e3t with
q2(t) = A2ie_at + A22e2t + A23e_3t with
q3(t) = A3ie_at + A32e_c2t + A33e_cx3t with
A31 + A32 + A33 =0
equation 1 may be normalized to 2a by setting
A1 =
XII + X12 + X13
VP = Q/C0
T112 = 0.693/a3
Fcr = 1/(A11/a1 + A21/2 + A3j/a3)
P [A1/ai + A21/a2 + A31/a3]2
P+E = A11/(a1)2 + A2/(a2)2 + A31/(a3)2
Synthesis rate = Vp x Cp x Fcr
with Cp stands for plasma 132m concentration and Vp for plasma
volume.
All calculations and data handling were done with the equa-
tion solver "EUREKA" from Borland and EXCEL 3.0 from
Microsoft.
Results
Stability of the labeled /32m
'251-/32m remaining in the syringe after administration was
stored at 4°C, and some samples were tested three months later.
Neither chromatography, nor SDS-PAGE analysis showed
(Eq. 2c) breakdown or aggregation of '251-/32m, indicating that the la-
beled material remained unchanged and that no spontaneous
deiodination had occurred. Chromatograms of plasma taken
from 1 to 720 minutes after 2m injection show the absence of
(Eq. 3) radioactive peak higher than 12 kDa, indicating the absence of
aggregation or of binding to a carrier protein but the presence of
degradated /32m (Fig. 1). Moreover, the method cannot exclude
a possible binding to cell membrane. PAGE-SDS analysis
shown in Figure 2 demonstrates that /32m was only found intact
(Eq. 4) or fully degradated.
Free iodine generation
Traces of free iodine were measured one minute after admin-
istration of '251-132m and were negligible at five minutes. This
free iodine originated from radiolabeled material where it
represented 0.3 to 3% of the radioactivity. It was injected
together with '251-J32m and diffused in total body water. After
this time, free iodine increased progressively and free iodine
measured 10 minutes after tracer injection was considered to
result from 1251-/32m catabolism. In anephric patients, the
diffusion volume of free iodine has been calculated to be 34.6%
of body weight [281. Assuming that diffusion of free iodine in the
(Eq. 5) iodine space is instantaneous, one can estimate 132m degrada-
tion rate from concentration of free iodine in plasma and in
E 6' urine and dialysate. Figure 3 shows the cumulative curve of freeq. iodine in a representative case. In controls, free 125! recovered
in urine within 96 hours accounted for almost 100% of injected
(Eq. 7) radioactivity.
compartment j at time t [q(t)] is described by the following
equations:
A11 + A12 + A13 = 1 (Eq. 2a)
A21+A22+A23=0 (Eq. 2b)
Plasma volume (V0) was calculated by extrapolation of the
early part of the curve to zero time according to the relation:
where Q is the total amount of injected /32m, and C0 the
concentration of the tracer in the plasma at time t = 0.
Half life (T112) was calculated from the slowest exponential
constant a3 with the relation:
The system of three differential equations describing the
compartmental amount of tracer allows calculation of fractional
catabolic rate (Fcr), f32m synthesis rate and the ratio of plasma
pool (P) to total 32m pools (P + E) according to Matthews [251,
Reeve and Bailey [26] and Nosslin [27]:
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Fig. 2. Electrophoreric analysis on PAGE-
SDS gels of injected j32m (lane 1) and serum
samples from patient SAB (lanes 2—13) from
left to right samples are in chronologic order;
1, 3, 5, JO, 30 minutes and 1, 2, 4, 6 hours.
Inclusion volumes were 2 l (lanes 2—5) and
10 l (lane 2—10). The radioactivity associated
to f32m was detected by 24 hour exposure to
Kodak XAR film at —70°C.
Fig. 3. Curves of'251-f32m in CAR. Radioactivity bound to j32m in the
plasma ( ); free iodine in the plasma (.-.- -- —). A cumulative
fraction retained (total body f3m bound radioactivity) can be calculated
by substraction of the free iodine generated from the injected radioac-
tivity, this fraction represents the sum of plasmatic and extraplasmatic
compartments. It was calculated for each interval of time (----). The
extravascular part was obtained by substraction of the plasma activity
from the cumulative fraction retained (— — —
—). Dl refers to the first
dialysis session.
Turnover studies using the three compartment model
Representative curves of plasma '251-/32m activity plotted
against time are shown in Figure 4. It was possible to document
a two exponential decay in healthy controls. In uremic patients,
whatever the technical supportive therapy (hemodialysis, he-
mofiltration or CAPD), the exponential decay did not fit with a
two exponential solution and a three exponential model was
therefore applied.
Plasma volumes are presented in Table 1. The mean plasma
pool of /32m was 5.43 mg in controls. It was significantly
increased in uremic patients in proportion to plasma f32m levels.
/32m partition between plasmatic and extraplasmatic pools, as
documented by the ratio of plasmatic pool to the sum of the
pools (Table 2), did not appear to be influenced by the dialysis
technique.
In Table 2 the calculated haif-lifes of 125! /32m are shown.
Median values were 1.88 hours for controls and 44.4, 29.8, 42.3
and 48.1 hours for HD CUP, HD AN69, HF and CAPD
patients, respectively. For more precise calculation, the third
exponential term was estimated in some patients taking into
account the whole data collected during the study, which
included radioactivity loss in urine (if any), dialysate and
binding onto artificial membrane. However, it did not differ
significantly from calculations performed on the early part of
being ten to twenty times less, whatever the dialysis technique
in use.
As dialysis represented for some patients an important loss of
/32m, calculation of the synthetic rate has been done with a
mean serum concentration corresponding to the hours following
the tracer infusion. In this period which precedes the dialysis by
no more than 24 hours, there is no re-equilibration between
compartments by diffusion, however, some imprecision may
exist as plasmatic volume might change during this period.
The f32m synthesis rate was between 2.22 and 5.73 mg/kg/day
in controls, and between 1.23 and 9.09 mg/kg/day in dialysis
patients. In pooling the data, the mean synthesis rate was 3.68
1.43 in controls and 4.56 2.51 mg/kg/day in uremic patients,
but the differences between patients and controls was not
significant. Patients treated with Cuprophane had the highest
values (5.70 2.34 mg/kg/day), whereas those treated by
hemofiltration had the lowest (2.19 0.71 mg/kg/day).
f32m loss during dialysis
Cuprophane membrane was not permeable to 132m and did
not bind significant amounts of the protein. Conversely, the two
highly permeable membranes used in the study removed f32m
both by filtration and by specific binding. The technical condi-
tions of dialysis did not allow accurate clearance measurements
on the dialysate side. In addition, the study was not designed to
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and D3 refer to beginning of the dialysis
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Table 2. Calculated parameters from observed values and from computed data
Loss by Loss by Free iodine
Name
.
Dialysis
treatment
T112
hr
Fcr
min1
.
Synthetic rate
mg/k/day
Sp
Sp + Se
dialysis diuresis
A55
accumulation Captation
mg/k/day mg/k/day
JPR Control 1.48 0.0344 4.05 0.289 0 1 0 0
CLV Control 1.77 0.0473 5.73 0.259 0 1 0 0
JMH Control 4.83 0.0283 2.22 0.312 0 1 0 0
SRI Control 1.93 0.0291 2.39 0.275 0 1 0 0
JBR Control 1.93 0.0262 3.99 0.298 0 1 0 0
POQ HD cup 52.5 0.0022 9.09 0.117 0.090 0.03 0.456 5.03 4.00
SAB HD cup 50.3 0.0012 6.45 0.209 0.000 0 0.420 2.71 3.74
HOU HD cup 37.0 0.0016 5.83 0.215 0.100 0 0.562 3.28 2.56
CAR HD cup 25.1 0.0022 4.17 0.227 0.100 0.05 0.283 1.15 2.91
DEL HD cup 44.4 0.0011 2.97 0.240 0.060 0.06 0.691 2.02 0.89
PIQ HD AN69 20.9 0.0019 4.46 0.304 0.560 0 0.868 3.37 0.51
HEL HD AN69 26.7 0.0021 7.02 0.238 0.570 0 0.316 1.48 5.01
CIV HD AN69 45.3 0.0013 6.17 0.245 0.740 0 0.723 2.65 2.82
TAD HD AN69 29.8 0.0020 6.79 0.216 0.500 0 0.598 3.75 2.52
LAM HD AN69 50.3 0.0009 1.23 0.262 0.360 0 0.775 0.69 0.20
MAZ HF 40.7 0.0014 1.90 0.225 0.630 0 0.765 1.10 0.33
JAC HF 44.0 0.0007 1.86 0.206 1.710 0 1.184 0.14 0.00
JAO HF 36.7 0.0014 3.38 0.238 1.300 0.25 0.288 0.47 1.19
OLI HF 57.8 0.0007 2.19 0.289 1.200 anephric 0.557 0.55 0.43
SAL CAPD 64.6 0.0014 2.23 0.138 1.670 0 0.539 0.53 0.44
DUF CAPD 41.3 0.0019 8.86 0.154 2.020 0 0.366 2.42 4.29
HAU CAPD 48.1 0.0008 2.98 0.301 1.310 0 0.510 0.92 0.88
S, represents the amount of /32m in the plasmatic volumes and S the amount in all extravascular /32m spaces. Loss by dialysis and diuresis was
determined by ELISA. Free iodine accumulation and captation were calculated with the extended model.
measure /32m binding onto artificial membranes as it can be represented 64 to 90 mg with AN69 and 50 to 90 mg with
done with LIodine. Nevertheless an estimation can be done
from the data of an iSiIp2m kinetics study with total body
counting [291. In this work, the dialysis cartridges were washed
after use then counted in the total body counter to calculate the
binding capacity of the different materials in mg of /32m per
square meter. In the actual study, the total amount of /32m
recovered in the dialysate was added to the estimation of the
amount bound onto the artificial membrane, and the sum
polysulfone.
Dialyzer clearances were measured from the blood side. We
measured J32m mass transfer from changes in plasma f32m
specific activity, assuming that plasma /32m levels reflected /32m
concentrations in the extrarenal volume which participates in
fluid exchange during dialysis, that is, 20% body weight; we
calculated that amounts of 114 to 246 mg and 71 to 270 mg were
removed by dialysis with AN69 and HF, respectively. These
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changeable compartment model. '25I-2m had diffused in
plasma and extraplasmatic compartments, whereas free iodine
had diffused in the iodine space. The increment of free iodine
corresponded to the decrease of '251-/32m as a consequence of
the catabolism of the protein, as illustrated in Figure 3. In the
three compartment model, the quantity of labeled material in
each of the compartments may be expressed as a function of
time by an equation involving three exponential terms, the
exponential constants (a1) being identical for all the compart-
ments. Once the two faster exponentials have decayed the three
compartmental masses can be represented by curves having the
same slopes. This was documented from 240 to 360 minutes
after injection of the tracer, since after the mixing period the
retention curve and the plasma specific activity curve ap-
proached straight lines. However, the terminal slopes of these
curves were different, the plasma curve having the highest
slope, which indicated that the tracer had left the plasma
compartment at a faster rate than could be accounted for. A
similar discrepancy was observed in all dialyzed patients with
the exception of few HF patients, but not in healthy controls.
Conversely, the curve depicting tracer accumulation in the
extravascular compartments had a final slope lower than that of
the total retention curve, suggesting that in addition to the two
extraplasmatic compartments, another compartment with a
negligible return of /32m might be taken into account. As tracer
experiments of sufficient duration appear unreliable, this com-
partment may be analytically considered as a non-exchangeable
compartment.
Proposed model for f32m turnover
Time, minutes
Fig. 5. Mean values of f32m measured by ELISA (•) or radioactivity
associated with intact f32m (0) and degradation products (0) in the
plasma of each set of dialyzed patients during the first dialysis session.
All data are expressed as a ratio of the first sample values.
values are higher than those calculated from the dialysate side,
indicating that the epuration concerns the plasmatic volume and
only a part of the extraplasmatic volume. f32m mass transfer
could not be calculated from total j32m pools.
The cumulative f32m loss by dialysis on the three dialysis
sessions of a week was divided by 7 to obtain an estimation of
daily elimination by dialysis and to compare this value to the
daily synthesis. Similarly, the total f32m recovered in the urine
from a week was divided by 7 to compare these data to the daily
synthesis. In HD treated patients, the intact tracer recovered in
urine and dialysis fluids represented only a small proportion of
the daily synthesis. By contrast in HF or CAPD treated patients
it represented between 30 and 100% of the daily synthesis
(Table 2).
Kinetics of '251-/32m and free 125J are shown in Figure 5. The
use of highly permeable membranes was associated with the
f32m shift into the dialysate. Conversely, the use of Cuprophan
membrane was not associated with the appearance of f32m in the
dialysate, and consequently serum '251-/32m relative activity
remained constant throughout the session.
Limits in using the three compartment model
In uremic patients, plasma activity-time curves were adjusted
to a three exponential solution corresponding to a three ex-
Figure 6 shows the schematic representation of the postu-
lated model established to take into account the loss of tracer
from the exchanging compartments. This six compartment
model is derived from studies on albumin turnover by Berman
and Schoenfeld [301 and Lewallen, Berman and RaIl [31]. It
includes the three exchanging compartments previously used to
calculate metabolic constants, defined as "plasmatic" for com-
partment 1, "extraplasmatic" for compartments 2 and 3 and
additional compartments. Compartment 4 corresponds to the
compartment in which /32m is sequestered, thereby considered
as a non-exchangeable compartment. Compartment 5 repre-
sents the compartment in which non-excreted labeled degrada-
tion products accumulate. Compartment 6 represents the com-
partment through which degradation products ("free iodine")
are released from the body via either the functional kidney or
dialyzer.
In uremic patients free iodine was mainly cleared by dialysis.
As collection of dialysis fluids and urine was not carried out
long enough to determine the total value of free iodine, free
iodine production can be computed as follows:
Free iodine amounts recovered into dialysis fluids and urine
were added to the total body accumulation already calculated.
If q5(t) represents the cumulative free iodine accumulation in
the total body, a plot of the logarithm of free iodine generation
per units of time dq5(t)/dt shows that the terminal slope (a3) is
comparable to the terminal slope of the plasma curve. This
slope has been determined at a time t1 (between days 2 and 3)
when all compartments were considered in an equilibrium state.
If we assume that this slope remained constant indefinitely, the
total free iodine generation after this time t1 can be computed
/ treated as i
exchanging corr
x3' _--- A52
1 Plasma compartment
A5,
Free iodine output
* V
Non-excreted labelled
6 degradation products
A32
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Slowly exchanging
extravascular compartment
Rapidly exchanging
extravascular compartment
Fig. 6. Schematic representation of the
metabolic model. S3 was the amount of f3m in
the Jth compartment (mg), with ST sum of S;
q(t) was the quantity of tracer in
compartment j at time t (fraction of injected
dose); A3 was the fraction of S3 or q3(t)
transferred to compartment i from
compartment j per hour (a fractional turnover
rate). The labeled j32m is injected into a
primary distribution volume corresponding to
compartment 1 (also named V) and assumed
to distribute into this and extravascular
compartments 2 and 3. Compartment 4 was a
postulated compartment treated as
nonexchanging compartment. Degradation
products accumulated into compartment 5 and
can be excreted by dialysis or in urine, if any.
from data, then A55, the asymptotic value of q5(a) at t, and the
dimension of q5, can be calculated. The calculated free iodine
generation can be transformed in J32m equivalent and represents
a pool of variable dimension according to the treatment (Table
2).
No measurement of the postulated compartment 4 can be
done directly. The asymptotic value of q4(t) must be equal to
1 — A55, and the slopes of the exponential terms must be the
same as the plasma curve. However, the individual turnover
rates A41, A42 and A43 cannot be calculated. To express the
radioactivity in compartment 4 as a function of time, we
assumed that the activity in compartment 4 is proportional to
activity in compartment 5 [31]. q4(t) was then calculated and
presented in Table 2.
From these above assumptions concerning q4(t), the total
radioactivity in compartments 2 and 3 can be calculated from
the relation:
q2(t) + q3(t) = 1 — [q1(t) + q4(t) + q5(t)] (Eq. 8)
The calculated curve is presented on Figure 7 for patient PIQ.
Discussion
Convincing studies have established a well accepted model of
plasma free f32m metabolism in healthy subjects with normal
functioning kidneys: the protein synthesized by nearly all
nucleated cells is filtered by the glomerulus with a sieving
coefficient of 0.97 [321. Within the kidney more than 98% of p2m
is degradated and no extrarenal route of catabolism is known
[18, 20—22]. The model best describing kinetics is the two
compartment model in which the size of the extraplasmatic pool
is two to three times the size of the plasmatic pool. The mean
/32m generation rate is in the order of 2 to 3 mg/kg/day 118, 19].
Such values have been confirmed in the five healthy controls
included in the study.
0 500 1000 1500 2000
Time, minutes
Fig. 7. Calculated data after modeling. Radioactivity bound to intact
tracer in the plasma ( ); radioactivity corresponding to free iodine
accumulation (— — ..) and captation (— — —); radioactivity in compart-
ment 2 plus 3 (
In uremic patients and particularly in patients on dialysis, the
metabolic studies are scarce and the results conflicting. Kinet-
ics have been depicted using either the two compartment model
as in healthy controls [18, 191 or the three compartment model
1331. All the time-activity plasma curves we have obtained after
administration of '251-132m could not be solved by the sum of
only two exponential components: they required at least three
exponential terms, that led us to use a priori the three compart-
ment model to calculate turnover parameters. However, it was
observed that the tracer left the plasmatic compartment faster
than the extraplasmatic compartment (retention volumes),
which suggests the presence of an additional compartment with
a slower exchange rate or even with no return to the plasma.
For this reason we consider that the three compartment model
was not suited to the data obtained in dialysis patients. We
a)
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•0
a)0
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0
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therefore proposed an extension of the model which takes into
account this additional non-exchangeable compartment. To
validate such a choice we had to fulfill the general assumptions
of the compartmental theory, that can be summarized as
follows:
(1) the metabolism of the labeled tracer molecule is identical to
that of the native molecule;
(2) after degradation of the tracer, the generated free iodine
diffuses immediately into vascular and extravascular spac-
es;
(3) there is no re-use of the labeled fragments produced by
catabolism, and in the case of a functional kidney their
excretion into urine is instantaneous;
(4) during the study, the system (subject) is in a metabolic
steady state;
(5) protein synthesis occurs in the intravascular compartment
before entering into extravascular compartments;
(6) catabolism occurs in compartment(s) exchanging with the
intravascular compartment instantaneously.
Each of these assumptions can be justified in the present
study.
(1) To avoid damage of the protein the iodine monochloride
method of McFarlane was used for labeling. Chromatogra-
phy and PAGE-SDS electrophoresis demonstrated that /32m
was indistinguishable from native /32m. In addition, the
labeled material remaining in the syringe after administra-
tion to the patient was stored at —20°C for one to three
months, then analyzed: the tracer remained stable indicat-
ing that no radiolysis had occurred under this conditions.
(2) The equilibration time for diffusion of free iodine was very
short, less than five minutes in all instances, as indicated by
the rapid disappearance of the small amount of free l25J
injected together with 125! 132m.
(3) In controls, degradation products were recovered in the first
urine collection at 30 minutes. Within 72 to 96 hours, the
entire amount of the tracer was recovered in urine as free
iodine.
(4) Patients on chronic hemodialysis have very stable /32m
levels [4]. Whatever the postdialysis change in plasmatic
/32m concentration, either increasing using cellulosic mem-
branes, or decreasing using high permeable membrane,
predialysis levels of the next session had returned to the
steady state concentration. In addition, all the patients
included in the study were in good condition and well
adapted to therapy. They had no infectious or inflammatory
diseases.
(5) and (6) These requirements have to be accepted with the
model.
The major new finding of the present study is the demonstra-
tion of a captation compartment in dialysis patients as it was
suggested by Odell et al [33]. The j32m influx into this compart-
ment varied from 0 (in a patient under hemofiltration) to 5
mg/kg/day, which may correspond to 1.5 glkg per year. As
assessed by non-TCA precipitable iodine generation there was
no measurable breakdown of this "capted" pm for the dura-
tion of the study. This does not preclude a slow degradation rate
or a structural modification of the molecule possibly associated
with amyloidogenesis, since the clinical expression of this
disease is frequent in long-term dialyzed patients and that the
longer the time exposure to cellulosic membrane the more
frequent is the carpal tunel syndrome due to /32m-related
amyloid deposition [34]. This captation compartment may be
associated with f32m binding on collagen [35] and fixed mac-
rophages in spite of the fact that they are not many at the edge
of amyloid deposits in synovial specimen [36]. Trace accumu-
lation in this compartment may be demonstrated in scintiscans
such as those recently obtained in uremic patients with amy-
loidosis using high doses of '311-132m [37, 38].
The T112 values of the slow exponential component of the
1251-132m was considerably lengthened in uremic patients when
compared with healthy controls. f32m plasmatic and extraplas-
matic diffusion volumes were similar to those already pub-
lished, that is, 53 mg/kg for plasmatic volume [14, 34], and 16 to
20% of body weight for extracellular fluid volumes [12, 13, 34,
39, 40]. The fractional catabolic rate we have calculated re-
mains independent of the presence of compartments 4 and 5
included in the model, and is mainly related to the precision
used in calculating the plasmatic volumes. Fcr was in the same
order of magnitude than the values reported in other studies [18,
19, 32, 38], at least ten times less than the normal values. Free
iodine which accumulates in body fluids results from an extra-
renal catabolism of the molecule, at least in anephric patients,
since '251-132m stored for more than a month did not generate
free iodine. The extrarenal metabolic pathways of 132m are
unknown. A proteolytic enzyme of the lysine-esterase family
has recently been described in amyloidosis deposits [41] and it
may require high substrate concentration to operate. Macro-
phages are candidates for binding and degradation, as suggested
in the rat [22] in which the distribution of /32m was shown to
depend on the macrophage content of each tissue. One cannot
exclude that specific /32m binding sites demonstrated on brush
border of proximal tubular cells [42, 43] may be expressed on
other tissues.
For patients having stable /32m levels, the synthetic rate of
the protein must be equivalent to the catabolic rate, and
patients on hemodialysis had a slight increase of /32m synthesis
rate (P < 0.01 calculated with Kruskal and Wallis analysis of
variance) when compared to controls or to patients under HF or
CAPD, with the exception of one CAPD patient (DUF). The
synthesis rate in all dialysis patients was positively correlated
with plasma /32m concentration. We were unable to document
any significant effect of membrane type on 132m generation
among HD patients, whereas in vitro cellulosic membrane, but
not polyacrylonitrile or polysullone membranes, were reported
to induce f32m release from circulating mononuclear cells [44].
Each dialysis session transiently disrupted the steady state.
However, we considered (as others have previously) that the
basic assumptions of the compartmental theory still held.
Postdialysis 2m levels compared with predialysis levels de-
creased when using highly permeable membranes: by 25% with
AN69 and by 50% with the hemofiltration technique. In con-
trast, a slight increase was documented when using the Cu-
prophane membrane which is not permeable to protein and has
no specific binding effect. The slightly delayed exchange be-
tween plasmatic and extraplasmatic pools during dialysis may
argue for fluid changes and re-equilibration, rather than stimu-
lation of 2m synthesis induced by blood contact to so-called
bioincompatible cellulosic membranes. However, stimulation
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of f32m mRNA synthesis has been documented in lymphocytes
exposed to cellulosic membranes [45].
The amount of 132m removed during a session performed with
highly permeable membranes used either in the dialysis or the
hemofiltration mode could be equivalent to the amount synthe-
sized during a few hours or a day. Hemofiltration, if performed
on a daily basis, might compensate /32m generation, but practi-
cal application of such solution remains questionable on clinical
grounds, even in patients with invalidating amyloidosis. CAPD
does not appear to be a better solution to remove f32m and
prevent amyloidosis.
In conclusion, '25I-32m turnover studies in dialyzed patients
confirm the major role of the kidney in /32m breakdown. The
dramatic decrease of f32m catabolism seems to be associated
with a slight increase in synthesis rate, at least in patients
dialyzed with cellulosic membrane, and this may account for
the dialysis bioincompatibility concept. Synthetic dialysis mem-
branes which are permeable to and bind f32m may be useful in
postponing 132m-derived amyloidosis by balancing, at least
partially, /32m generation. Such clinical background validates
the multicompartmental model we propose in which a captation
compartment may indicate amyloid potential, but deposition of
/32m is probably insufficient by itself to induce polymerization of
intact or partially degradated 2m into amyloid filaments.
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